Navigation Links
Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research
Date:1/6/2009

NEW YORK, Jan. 6 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation awarded a total of about $2.7 million to four industry research teams for pre-clinical research on potential new treatments for Parkinson's disease.

The funding was awarded under the Foundation's Therapeutics Development Initiative. This program, first launched in 2006, supports and bolsters industry-focused efforts on Parkinson's research. TDI is part of MJFF's focus on 'de-risking' preclinical PD research for biotech and pharmaceutical companies, thus expanding and catalyzing industry investments in Parkinson's drug development. By adding MJFF resources to companies' own, the Foundation aims to make Parkinson's therapies a more attractive bet and help to push research further along the pipeline.

The funded projects are listed below. Full information, including grant abstracts and researcher bios, is available on the Foundation's Web site -- www.michaeljfox.org.

Cerebrospinal Fluid (CSF) Biomarkers of Microtubule-mediated Axonal Transport for Monitoring of Disease Progression and Therapeutics Interventions in Parkinson's Disease

Patrizia Fanara, Ph.D., KineMed, Inc.

Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinson's Disease

Vincent Allen Florio, Ph.D., Omeros Corporation

Development of ER-beta Agonists for the Treatment of Parkinson's Disease

Roger Olsson, Ph.D., and Krista McFarland, Ph.D., Acadia Pharmaceuticals, Inc.

Multiphosphatase Inhibitors as Therapeutics for Parkinson's Disease

Arnon Rosenthal, Ph.D., and Franz F. Hefti, Ph.D., ShanaRX

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the decade through an aggressively funded research agenda. The Foundation has funded over $130 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinsons Disease
3. New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinsons Clinical Trials
4. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
5. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
6. The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards
7. Michael J. Fox Foundation Awards $2.4 Million for Validation of Nine Promising Therapeutic Targets for Parkinsons Disease
8. Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinsons Therapeutics
9. Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee
10. Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinsons Disease Under Rapid Response Innovation Awards 2008
11. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, ... to its patient care management module. Using this new feature, sleep physicians can ... been initiated on continuous positive airway pressure (CPAP), oral, or other forms of ...
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place ... to a special report in the May issue of Consumer Reports focused on heart ... ranking for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... the continuation of its strategic partnership with and platinum sponsorship of Global Spine ... the safe and effective management of complex spine deformity cases, particularly in children. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG CNS Healthcare Solutions debuted ... capabilities at Telehealth 2.0, the American Telemedicine Association’s national conference. , BYOD has ... with a pre-programmed tablet in a remarkably easy-to-use kit for patients. “BYOD is ...
(Date:4/24/2017)... ... April 24, 2017 , ... The Santana Telehealth Project ... 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on April 23 in ... for using telemedicine to improve the lives of the poor and underserved in other ...
Breaking Medicine News(10 mins):